1. Rosen HR. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429–38.
2. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transplant. 2008;14(2):36–44.
3. Foster GR, Goldin R. Management of chronic viral hepatitis. Taylor Fr Gr. 2005;2nd Edition.
4. Shinn JH, Liang KC. Chronic hepatitis C and Diabetes Mellitus. Chinese J Med Assoc. 2006;69(4):143–5.
5. Alter MJ. Epidemiology of Hepatitis C virus. J Hepatol. 1997;26:625–55.
6. Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22(10):853–61.
7. Elfiky AA, Elshemey WM, Gawad W, Desoky O. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J. 2013;32(1):75–80.
8. Mehta SH. Hepatitis C Virus infection and incident Type 2 diabetes. J Hepatol. 2003;38(1).
9. Imam K. Clinical features, diagnostic criteria and pathogenesis of diabetes mellitus. Adv Exp Med Biol. 2012;771:340–55.
10. Peck T, Price C, English P, Gill G. Oral health in rural South African type 2 diabetic patients. Trop Doct. 2006;36(2):111–2.
11. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82.
12. H K, R S, A Z, G F, A. S. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin. 2000;75:355–9.
13. Zein CO, Levy C, Basu A, NN Z. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100:48–55.
14. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37(6):647–52.
15. Naing C, Mak JW, Ahmed SI, M. Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol. 2012;18(14):1642–51.
16. Nwokediuko SC, Oli JM. Hepatitis C Virus Infection in Nigerians with diabetes mellitus. Niger J Clin Pract. 2008;11(2):94–9.
17. Ejele O, Erhabor O, Nwauche CA. The risk of transfusion-transmissible viral infections in the Niger-Delta area of Nigeria. Sahel Med J. 2005;8(1).
18. Balogun WO, Adeleye JO, Akinlade KS, Kuti M, Otegbayo JA. Low prevalence of hepatitis-C viral seropositivity among patients with type-2 diabetes mellitus in a tertiary hospital. J Natl Med Assoc. 2006;98(11):1805.
19a. Ndako,J.A., Nwankiti,O.O., Onovoh,E.M., Adekeye,A.E.,Choji,T.P.,Alesa,M.U and Alarape,A.J.. Screening response to Hepatitis C Virus antibodies among Diabetic patients attending UITH Nigeria,Current Research Journal of Biological Sciences.2011;3(6): 542-546
19b. Demitrost L, Ranabir S. Thyroid dysfunction in type 2 diabetes mellitus: A retrospective study. Indian J Endocrinol Metab. 2012;16(Suppl 2):S334–335.
19c. Gray H, Wreghitt T, Stratton IM, Alexander GJ, Turner RC, O’Rahilly S. High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med. 1995;12:244–249
20a. Ndako,J.A., Echeonwu,G.O.N., Shidali,N.N., Bichi,I.A., Paul,G.A., Onovoh,E. and Okeke,L.A. Occurrence of Hepatitis C Virus infection in type 2 diabetic patients attending Plateau state specialist hospital Jos Nigeria Virology Journal,2009; 6:98 doi: 10.1186/1743-422X-6-98.
20b. Gacche RN, Al-Mohani SK. Seroprevalence and Risk Factors for Hepatitis C Virus Infection among General Population in Central Region of Yemen. Hepatitis Research and Treatment. 2012: 1-4.
21. Mehta SH, Pankow FLBSASJS, Netski D, Coresh J, Szklo M, Thomas DL. Hepatitis C Virus infection and incident Type 2 diabetes. J Hepatol. 2003;38(1).
22. Klevens RM, Miller J, Vonderwahl C, Speers S, Alelis K, Sweet K, et al. Population-based surveillance for hepatitis C virus, United States. Emerg Infect Dis. 2009;15(9):1499.
23. Lee SR, Kardos KW, Schiff E. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods. 2011;172(1–2):27–31.
24. Qureshi H, Bile KM, Jooma R, Alam SE, Afrid. HUR. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Heal J. 2010;16(8):15–23.
25a. Simo R, Hernadez C, Genesa J, Jardi R, Mesa J. High prevalence of Hepatitis virus infection in diabetic patients. Am Diabetes Assoc. 1996;19(9):998–1000.
25b. Mason, A. L., J. Y. Lau, N. Hoang, K. Qian, G. J. Alexander, L. Xu, L. Guo, S. Jacob, F. G. Regenstein, R. Zimmerman, J. E. Everhart, C. Wasserfall, N. K. Maclaren, and R. P. Perrillo. 1999. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328-333
26. Cardinal GF, Di Martino V, Lambrey G, Nalet B, Anciaux M. Prevalence of hepatitis C infection and risk factors in hospitalized diabetic patients: results of a cross-sectional study. Eur J Gastroenterol Hepatol. 2008;20(9):829–36.
27a. Francesca W, Lutje. V, Declan D, Valerie S. Sexual transmission of Hepatitis C Virus infection in a heterosexual population: A systematic review [version 1; referees: 2 approved]. HRB Open Res. 2018
27b. Mueller, H. M., Pfaff, E., Goeser, T., Kallinowski, B., Solbach, C. &Theilmann, L. Peripheral blood leukocytes serve as a possibleextrahepatic site for hepatitis C virus replication.Journal of GeneralVirology, 1993; 74, 669-676.
28. Osi O, Sanaa MK. Hepatitis C in Developing countries. Acad Press. 2018;71–81.
29. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C. J Hepatol. 2009;